Clinical Trial Update: Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in AD Subjects Compared to HC [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating [123I] MNI-308 with SPECT as a marker of beta-amyloid deposition in Alzheimer's disease subjects. The study status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• [123I] MNI-308 (MNI-308)

Snippet

Sponsor: Molecular NeuroImaging | Conditions: Alzheimer Disease | Phase 1 | Status: TERMINATED